RT Journal Article
SR Electronic
T1 Genetic subtypes of prediabetes, healthy lifestyle, and risk of type 2 diabetes: Prospective cohort study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.27.22283972
DO 10.1101/2022.12.27.22283972
A1 Li, Yang
A1 Chen, Guo-Chong
A1 Moon, Jee-Young
A1 Arthur, Rhonda
A1 Sotres-Alvarez, Daniela
A1 Daviglus, Martha L.
A1 Pirzada, Amber
A1 Mattei, Josiemer
A1 Perreira, Krista M.
A1 Rotter, Jerome I.
A1 Taylor, Kent D.
A1 Chen, Yii-Der Ida
A1 Wassertheil-Smoller, Sylvia
A1 Wang, Tao
A1 Rohan, Thomas E.
A1 Kaufman, Joel D.
A1 Kaplan, Robert
A1 Qi, Qibin
YR 2023
UL http://medrxiv.org/content/early/2023/01/05/2022.12.27.22283972.abstract
AB Objectives To cluster participants with prediabetes with five type 2 diabetes (T2D)-related partitioned polygenetic risk scores (pPRSs) and examine the risk of incident diabetes and the benefit of adherence to healthy lifestyle across clusters.Design Prospective cohort studySetting Hispanic Community Health Study/Study of Latinos (HCHS/SOL), US; UK Biobank (UKBB), UK.Participants 7,227 US Hispanic/Latinos without diabetes from HCHS/SOL, including 3,677 participants with prediabetes. 400,149 non-Hispanic whites without diabetes from UKBB, including 16,284 participants with prediabetes.Main outcome measures Prediabetes was defined by fasting plasma glucose (fasting glucose) between 100-125 mg/dL, 2-hour oral glucose tolerance test (OGTT 2h glucose) between 140-199 mg/dL, or hemoglobin A1c (HbA1c) between 5.7% and 6.5%. Diabetes was defined by fasting glucose levels ≥126 mg/dL, 2h glucose after OGTT ≥200 mg/dL, HbA1c ≥6.5%, current use of anti-diabetic medications, or medical record. Five pPRSs representing various pathways related to T2D were calculated based on 94 T2D-related genetic variants. Health lifestyle score was assessed with five modifiable risk factors, including body mass index (BMI), smoking, alcohol drinking, physical activity, and diet for T2D.Results Using K-means consensus clustering on five pRPSs, six clusters of individuals with prediabetes were identified in HCHS/SOL, with each cluster presenting disparate patterns of pPRSs and different patterns of metabolic traits. Except cluster 3 which was not detected, the other five clusters were conformed in participants with prediabetes in UKBB, with each cluster showing the similar patterns of pPRSs to their corresponding cluster in HCHS/SOL. At baseline, proportion of impaired glucose tolerance (IGT)/impaired fasting glucose (IFG) and glycemic traits in HCHS/SOL (fasting glucose, OGTT 2h glucose, and HbA1c) were not significantly different across six clusters (P=0.13, P=0.62, P=0.35, P=0.96, respectively). In UKBB, random glucose and HbA1c at baseline did not show significant difference across five clusters (P=0.43, P=0.71, respectively). Although baseline glycemic traits were similar across clusters, cluster 6, which featured a very low proinsulin score, exhibited elevated risk of incident T2D in both cohorts (risk ratio [RR]=1.39, 95% confidence interval [95% CI]=[1.10, 1.76] vs. cluster 1 in HCHS/SOL; hazard ratio [HR]=1.29, 95% CI=[1.00, 1.69] vs. cluster 1 in UKBB; Combined RR/HR=1.34 [1.13, 1.60]). To explain the elevated risk of incident T2D in cluster 6, interactions between proinsulin score and other three pPRSs (Beta-cell score, Lipodystrophy-like score, Liver-lipid score) and sum score were detected (P for interaction=0.001, 0.04, 0.02 and 0.002, respectively). Cluster 5 showed an increased risk of incident T2D in UKBB (HR=1.35 [1.05, 1.75] vs. cluster 1) and in the combined analysis with HCHS/SOL (RR/HR=1.29 [1.08, 1.53]), although its risk of T2D was not significantly different from cluster 1 in HCHS/SOL (RR=1.23 [0.96, 1.57]). Inverse associations between the lifestyle score and risk of T2D were observed across different clusters, with a suggestively stronger association in Cluster 5 compared to Cluster 1, in both cohorts. Cluster 5 showed reduced risk of incident diabetes caused by healthy lifestyle score (RR=0.65 [0.47, 0.89], HR=0.71 [0.62, 0.81], respectively. Combined RR/HR=0.70 [0.62, 0.79]). Among individuals with a healthy lifestyle, those in Cluster 5 had a similar risk of T2D compared to those in Cluster 1 (combined RR/HR=1.03 [0.91-1.18], P>0.05).Conclusions This study identified genetic subtypes of prediabetes which differed in risk of progression to T2D, with two subtypes showing relatively high risk of T2D over time. Favorable relationship between healthy lifestyle and risk of T2D was observed, regardless of their genetic subtypes. Participants in one subtype with higher risk of T2D may realize extra benefits in terms of risk reduction from a healthy lifestyle.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Hispanic Community Health Study/Study of Latinos is a collaborative study supported by contracts from the National Heart, Lung, and Blood Institute (NHLBI) to the University of North Carolina (HHSN268201300001I / N01-HC-65233), University of Miami (HHSN268201300004I / N01-HC-65234), Albert Einstein College of Medicine (HHSN268201300002I / N01-HC-65235), University of Illinois at Chicago (HHSN268201300003I / N01-HC-65236 Northwestern Univ), and San Diego State University (HHSN268201300005I / N01-HC-65237). The following Institutes/Centers/Offices have contributed to HCHS/SOL through a transfer of funds to the NHLBI: National Institute on Minority Health and Health Disparities, National Institute on Deafness and Other Communication Disorders, National Institute of Dental and Craniofacial Research, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Neurological Disorders and Stroke, and NIH Institution-Office of Dietary Supplements. This work is supported by the National Institute of Environmental Health Sciences (R01ES030994) and the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119268). Other funding sources for this study include R01HL060712, R01HL140976, and R01HL136266 from the NHLBI; and R01DK120870 and the New York Regional Center for Diabetes Translation Research (P30 DK111022) from the NIDDK. This research has been conducted using the UK Biobank Resource under Application Number 56483 (required by UKBB. This study was supported in part by the National Center for Advancing Translational Sciences, CTSI grant UL1TR001881, the National Institute of Diabetes and Digestive and Kidney Disease (NIDDK) Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center, and NIDDK contract UM1DK078616. Infrastructure for the CHARGE Consortium is supported in part by the National Heart, Lung, and Blood Institute (NHLBI) grant R01HL105756. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:HCHS/SOL was approved by the institutional review boards at Albert Einstein College of Medicine. UKBB has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB) approval. Informed consent was implied with the return of the self-administered questionnaires. This approval means that researchers do not require separate ethical clearance and can operate under the RTB approval.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript